Plasmodium Falciparum Malaria
Pipeline by Development Stage
Drug Modality Breakdown
Infectious Diseases is an $11.9B market dominated by HIV and hepatitis C treatments in their peak revenue phases, reflecting a mature but stable therapeutic area.
Key Trends
- HIV antiretroviral dominance: Nucleoside Reverse Transcriptase Inhibitors account for 44% of spending
- Patent cliff pressure: $2.8B in revenue from major products facing LOE between 2027–2031
- High trial velocity: 9,337 active trials indicate sustained pipeline development despite market maturity
Career Verdict
Infectious Diseases offers stable, well-compensated roles with strong commercial demand, but limited growth upside—ideal for risk-averse professionals seeking established franchises rather than high-growth opportunities.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | BIKTARVY (bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate) | Gilead Sciences | $3.2B | 27% | Peak | Stable | 10.5yr |
| 2 | EPCLUSA (velpatasvir and sofosbuvir) | Gilead Sciences | $877M | 7% | Peak | Stable | 8.2yr |
| 3 | TIVICAY (dolutegravir sodium) | GSK | $657M | 6% | Peak | Declining | 4.1yr |
| 4 | TRIUMEQ (abacavir sulfate, dolutegravir sodium, lamivudine) | GSK | $632M | 5% | Peak | Declining | 4.1yr |
| 5 | GENVOYA (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) | Gilead Sciences | $626M | 5% | Peak | Stable | 6.9yr |
Drug Class Breakdown
backbone of HIV treatment, stable demand
hepatitis C treatment, mature market
boosting agents in combination regimens
niche mechanism, limited growth
Career Outlook
StableInfectious Diseases offers predictable career progression and above-average compensation in Commercial roles, supported by 780 current openings and sustained demand from market incumbents. However, patent cliffs affecting $2.8B in near-term revenue (2027–2031) will compress margins and slow hiring after 2028, particularly in Commercial support and field-based roles. The area is best suited for mid-career professionals seeking stability over rapid growth, with limited appeal for early-career scientists pursuing innovation-driven research.
Breaking In
Enter via Commercial or Manufacturing roles at GSK, Sanofi, or Becton Dickinson to build market expertise and commanding salaries ($160K–$237K); avoid pure R&D tracks unless you target specific mechanisms like long-acting injectables.
For Experienced Professionals
Experienced professionals should pursue Market Access, Medical Affairs, or Commercial Leadership roles where patent cliff expertise commands premium compensation; consider consulting or biotech transition if R&D innovation is your priority.
In-Demand Skills
Best For
Hiring Landscape
Infectious Diseases hiring is heavily weighted toward Commercial roles (247 positions, 32% of total), reflecting mature market dynamics focused on market access and brand management. GSK and Becton Dickinson lead hiring (214 and 188 roles), but Gilead Sciences—the market leader by revenue—shows surprisingly low hiring (25 roles), signaling efficiency-driven operations. Salary progression favors Commercial ($275K avg) over R&D ($184K avg), indicating career acceleration through sales and marketing functions.
Top Hiring Companies
By Department
Strong Commercial hiring with premium salaries suggests Infectious Diseases is an excellent landing spot for brand, sales, and market access professionals, but limited R&D hiring indicates reduced innovation investment.
Competitive Landscape
10 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 28 trials with date data
Clinical Trials (28)
Total enrollment: 29,991 patients across 28 trials
SP Resistance and Falciparum Malaria Transmission
Evaluation of Safety and Efficacy of Artemether-Lumefantrine Tablets in African Infants and Children With Uncomplicated P. Falciparum Malaria
Pharmacokinetics, Safety, Tolerability and Efficacy of a New Artemether-lumefantrine Dispersible Tablet in Infants and Neonates <5 kg Body Weight With Acute Uncomplicated Plasmodium Falciparum Malaria
DSM265 Phase IIa Investigation Treating Plasmodium Falciparum or Vivax
Phase II AMA-1 Malaria Vaccine FMP2.1/AS02A Trial in Mali
Pentoxifylline in Children With Malaria
Phase I/II Trial of a Malaria Vaccine in Adults Living in the United States of America
CS DNA MVA Trial in Mampong, Ghana
SJ733 Induced Blood Stage Malaria Challenge Study
Effect of Imatinib on Suppression of Malaria Parasites in Patients With Uncomplicated Plasmodium Falciparum Malaria
Effectiveness of KAE609 in Reducing Asexual & Sexual Blood-stage P.Falciparum Infection & Infectivity to Mosquitos
Effect of Plasmodium Falciparum Exposure and Sickle Cell Trait on Infection Rates and Kinetics After IV Administration of PfSPZ Challenge
Phase I Pediatric FMP2.1/AS02A Trial in Mali
Assessment of Three Formulations of the Candidate Vaccine AMA 1 in Healthy Dutch Adult Volunteers
AMA1-C1/Alhydrogel + CpG 7909 for Malaria
FMP2.1/AS02A: Rabies Vaccine Malaria-Experienced Adults in Bandiagara, Mali
Experimental Vaccine for Plasmodium Falciparum Malaria
Experimental Vaccine for Malaria in Adults in Mali
Phase 1 Trial of a Malaria Vaccine in Young Kenyan Children
ICC-1132 - Candidate Vaccine Against P Falciparum Malaria
Artemisinin-resistant Malaria in Cambodia
Malarial Immunity in Pregnant Cameroonian Women
Hyperphenylalaninemia in Cerebral Malaria
Malaria Transmission and Immunity in Highland Kenya
Fetal Immunity to Falciparum Malaria
Malaria Prevalence in Children
Time to Infection With Malaria Parasites
Human Immunity to MSP-1 in Western Kenya
Related Jobs in Infectious Diseases
Vice President, Engineering
Vice President, Engineering
Vice President, Engineering
Vice President, Engineering
Director, Anti-infective Pharmacology
Executive Search Recruiting Coordinator
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.